Navigation Links
Odyssey Thera Announces Collaboration With Mitsubishi Tanabe Pharma Corporation, and Issuance of Core Patent in Japan
Date:5/15/2009

SAN RAMON, Calif., May 15 /PRNewswire/ -- Odyssey Thera, Inc. announced today the initiation of a collaboration with leading Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation. The alliance involves the analysis of drug candidates from a number of Mitsubishi Tanabe preclinical programs. Odyssey also announced the issuance of Japanese patent number JP 4262778, entitled "Protein fragment complementation assays for the detection of biological or drug interactions."

"We look forward to applying our patented human cell analysis technologies and proprietary drug profiling strategies to enhance Mitsubishi Tanabe's promising drug discovery programs," said Dr. John Westwick, President and CEO of Odyssey Thera. "Our partnership with Mitsubishi Tanabe, and the issuance of our Japanese patent, reflect our objective of making our unique knowledge base and enabling technologies available to quality partners around the globe."

Odyssey Thera will apply its patented Protein-fragment Complementation Assay (PCA), proprietary High Context Screening infrastructure, unique institutional knowledge, and state-of-the-art data analysis strategies in the collaboration to yield valuable insights related to drug selectivity, safety, and mechanisms of action. Financial terms of the collaboration were not disclosed.

About Odyssey Thera

Odyssey Thera, Inc. is a drug discovery company committed to identifying novel drug candidates for oncology and other chronic diseases. Odyssey Thera's live cell, pathway-based approach centers on its proprietary Protein-fragment Complementation Assay (PCA) technology and unique High Context Screening platform. Using these capabilities, Odyssey scientists have gained unique knowledge regarding cellular pathways and drug mechanisms. Odyssey's highly experienced team is using these capabilities to mine cellular systems and discover novel drug candidates for internal programs, and in partnerships with top pharmaceutical companies. To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
2. Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System
3. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
6. Odyssey Thera Granted U.S. Patent for Animal Imaging
7. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
8. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
9. Orexigen(R) Therapeutics to Present at Upcoming Meetings
10. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
11. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , February 16, 2017 ... infusion of innovative telemedicine application, new and leading ... are experiencing a boom worldwide. The healthcare sector ... of technologies, services and new therapies for companies ... (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
(Date:2/16/2017)... 16, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, today announced it ... and entered into a $5 million credit facility ... use the capital for general corporate purposes to ... the treatment of serious diseases treated by dermatologists. ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today the ... Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial ... physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative ...
(Date:2/16/2017)... , Feb. 16, 2017  Rhythm, ... rare genetic deficiencies that result in life-threatening ... a $41 million mezzanine round of financing ... OrbiMed, MPM Capital, New Enterprise Associates, Pfizer ... undisclosed public healthcare investment fund. Rhythm will ...
Breaking Biology Technology:
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
Breaking Biology News(10 mins):